Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

Cancer Letters

Volumn 312, Issue 2, 2011, Pages 228-234

  Tanaka, Ruriko ^a   Kimura, Shinya ^b   Ashihara, Eishi ^a,c   Yoshimura, Mariko ^b   Takahashi, Naoto ^d   Wakita, Hisashi ^e   Itoh, Kuniaki ^f   Nishiwaki, Kaichi ^g   Suzuki, Kenshi ^h   Nagao, Rina ^a   Yao, Hisayuki ^a   Hayashi, Yoshihiro ^a   Satake, Sakiko ^a   Hirai, Hideyo ^a   Sawada, Ken ichi ^d   Ottmann, Oliver G ⁱ   Melo, Junia V ^j   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NARITA RED CROSS HOSPITAL   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Japanese Red Cross Medical Centre   (Japan)

ⁱ GOETHE UNIVERSITY   (Germany)

^j INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

more..

Author keywords

Bcr abl; Leukemia; Mutation; Mutation biased PCR; Quenching probe

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; AUTOMATION; BLOOD SAMPLING; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIRECT SEQUENCING; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUTATION BIASED POLYMERASE CHAIN REACTION QP; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; QUENCING PROBE; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUTOMATION; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; YOUNG ADULT;

EID: 80053987395     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.009     Document Type: Article

References (21)

1. Goldman J.M., Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 2003, 349:1451-1464.
2. Gruber F., Mustjoki S., Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br. J. Haematol. 2009, 145:581-597.
3. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 2007, 7:345-356.
4. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-1029.
5. Tanaka R., Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev. Anticancer Ther. 2008, 8:1387-1398.
6. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
7. Deguchi Y., Kimura S., Ashihara E., Niwa T., Hodohara K., Fujiyama Y., Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leukemia Res. 2008, 32:980-983.
8. Redaelli S., Piazza R., Rostagno R., Magistroni V., Perini P., Marega M., Gambacorti-Passerini C., Boschelli F. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 2009, 27:469-471.
9. Vannucchi A.M., Pancrazzi A., Bogani C., Antonioli E., Guglielmelli P. A quantitative assay for JAK2 V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006, 20:1055-1060.
10. Soverini S., Martinelli G., Amabile M., Poerio A., Bianchini M., Rosti G., Pane F., Saglio G., Baccarani M. Italian cooperative study group on chronic myeloid leukemia; European LeukemiaNet-6th framework program of the European community, denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin. Chem. 2004, 50:1205-1213.
11. Gruber F.X., Lamark T., Anonli A., Sovershaev M.A., Olsen M., Gedde-Dahl T., Hjort-Hansen H., Skogen B. Selecting and deselecting imatinib-resistant clones, observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005, 19:2159-2165.
12. Khorashad J.S., Anand M., Marin D., Saunders S., Al-Jabary T., Iqbal A., Margerison S., Melo J.V., Goldman J.M., Apperley J.F., Kaeda J. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006, 20:658-663.
13. Kreuzer K.A., le Coutre P., Landt O., Na I.K., Schwarz M., Schultheis K., Hochhaus A., Dörken B. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann. Hematol. 2003, 82:284-289.
14. Tanaka R., Kuroda J., Stevenson W., Ashihara E., Ishikawa T., Taki T., Kobayashi Y., Kamitsuji Y., Kawata E., Takeuchi M., Murotani Y., Yokota A., Hirai M., Majima S., Taniwaki M., Maekawa T., Kimura S. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leukemia Res. 2008, 32:1462-1467.
15. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R. European LeukemiaNet, evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
16. Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114:5426-5435.
17. Nicolini F.E., Mauro M.J., Martinelli G., Kim D.W., Soverini S., Müller M.C., Hochhaus A., Cortes J., Chuah C., Dufva I.H., Apperley J.F., Yagasaki F., Pearson J.D., Peter S., Sanz Rodriguez C., Preudhomme C., Giles F., Goldman J.M., Zhou W. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009, 114:5271-5278.
18. Kim S.H., Kim D., Kim D.W., Goh H.G., Jang S.E., Lee J., Kim W.S., Kweon I.Y., Park S.H. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol. Oncol. 2009, 27:190-197 Y.
19. Qin, Chen S., Jiang B., Jiang Q., Jiang H., Li J., Li L., Lai Y., Liu Y., Huang X. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann. Hematol. 2011, 90:47-52.
20. Nicolini F.E., Corm S., Lê O.H., Sorel N., Hayette S., Bories D., Leguay T., Roy L., Giraudier S., Tulliez M., Facon T., Mahon F.X., Cayuela J.M., Rousselot P., Michallet M., Preudhomme C., Guilhot F., Roche-Lestienne C. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006, 20:1061-1066.
21. Kim D., Kim D.W., Cho B.S., Goh H.G., Kim S.H., Kim W.S., Lee J., Kweon I.Y., Park S.H., Yoon J.H., Kim N.D., Chun H. Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations. Leukemia Res. 2009, 33:1260-1265.